PLoS Pathogens (Jul 2009)

Structure and inhibition of the SARS coronavirus envelope protein ion channel.

  • Konstantin Pervushin,
  • Edward Tan,
  • Krupakar Parthasarathy,
  • Xin Lin,
  • Feng Li Jiang,
  • Dejie Yu,
  • Ardcharaporn Vararattanavech,
  • Tuck Wah Soong,
  • Ding Xiang Liu,
  • Jaume Torres

DOI
https://doi.org/10.1371/journal.ppat.1000511
Journal volume & issue
Vol. 5, no. 7
p. e1000511

Abstract

Read online

The envelope (E) protein from coronaviruses is a small polypeptide that contains at least one alpha-helical transmembrane domain. Absence, or inactivation, of E protein results in attenuated viruses, due to alterations in either virion morphology or tropism. Apart from its morphogenetic properties, protein E has been reported to have membrane permeabilizing activity. Further, the drug hexamethylene amiloride (HMA), but not amiloride, inhibited in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. We have previously shown for the coronavirus species responsible for severe acute respiratory syndrome (SARS-CoV) that the transmembrane domain of E protein (ETM) forms pentameric alpha-helical bundles that are likely responsible for the observed channel activity. Herein, using solution NMR in dodecylphosphatidylcholine micelles and energy minimization, we have obtained a model of this channel which features regular alpha-helices that form a pentameric left-handed parallel bundle. The drug HMA was found to bind inside the lumen of the channel, at both the C-terminal and the N-terminal openings, and, in contrast to amiloride, induced additional chemical shifts in ETM. Full length SARS-CoV E displayed channel activity when transiently expressed in human embryonic kidney 293 (HEK-293) cells in a whole-cell patch clamp set-up. This activity was significantly reduced by hexamethylene amiloride (HMA), but not by amiloride. The channel structure presented herein provides a possible rationale for inhibition, and a platform for future structure-based drug design of this potential pharmacological target.